Crossmark

The Cost-Effectiveness of Oral Semaglutide in Spain: A Long-Term Health Economic Analysis Based on the PIONEER Clinical Trials

Published Online: 2022-05-12

Published Print: 2022-07

Authors

Franch-Nadal, Josep

Malkin, Samuel J. P. https://orcid.org/0000-0003-1306-7784
Hunt, Barnaby

Martín, Virginia

Gallego Estébanez, María

Vidal, Josep
Funding

Funding for this research was provided by:

Novo Nordisk
License Information

Text and Data Mining valid from 2022-05-12

Version of Record valid from 2022-05-12
More Information

Article History

Received: 25 February 2022

Accepted: 30 March 2022

First Online: 12 May 2022

Document is current